ABSTRACT

The National Association of Comorbid Neurology Experts plays a key role in advancing neurological science and practice in comorbid conditions. The Association actively initiates and supports numerous research efforts to identify and study the interrelationships and interactions of various diseases affecting the nervous system. Through their efforts, the Association has become a leading platform for sharing best practices and knowledge in this field.

International co-operation is one of the central strategies for the development of the Association. It allows integrating the achievements of world science and adapting them to solve the urgent problems of domestic medicine.

Within the framework of the First International Council of Experts, the concept of development of the National Association of Experts in Comorbid Neurology was presented, as well as the expediency of concluding memoranda on international cooperation. International experts consider it advisable to recommend the widespread use of effective and safe drugs, including choline alphoscerate and chondroitin sulphate, by primary care specialists (district therapists, general practitioners) in general practice, starting from the early stages and in the progression of cognitive impairment and/or diseases of the musculoskeletal system.

KEYWORDS: expert advice, cognitive impairment, back pain, osteoarthritis, choline alphoscerate, chondroitin

For citation: Rachin A.P. Comorbid Neurology: Results of the First International Expert Council. Comorbidity Neurology. 2024; 1 (4): 59-67. https://doi.org/10.62505/3034-185x-2024-1-4-59-67

*For correspondence: Andrei P. Rachin, Dr. Sci. (Med.), Professor, President of the National Association of Experts in Comorbid Neurology, Moscow, Russia, e-mail: 7851377@gmail.com

REFERENCES

1.Kate Nadal-Ginard. When one thing interferes with another - comorbidity at the top of the agenda. New Millennium Medicine. 2012; 6: 22-24 (In Russ.)

2.Vertkin A.L., Skotnikov A.S. Comorbidity. Lvrach. 2013; 6: 66-69 (In Russ.)

3.Yakhno N.N., Lokshina A.B., Zakharov V.V. et al. Mild cognitive impairment in Russian population. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119 (5-2): 179–80. https://doi.org/10.17116/jnevro201911905S (In Russ.)

4.Lokshina A.B., Zakharov V.V., Grishina D.A., Koberskaya N.N., Mkhitaryan E.A., Posohov S.I., Yakhno N.N. Heterogeneity of the mild cognitive impairment syndrome (specialized outpatient service data analysis). Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (3): 34-41. https://doi.org/10.14412/2074-2711-2021-3-34-41 (In Russ.)

5.Zakharov V.V., Lokshina A.B. Physiological and pathological forgetfulness: differential diagnosis, approaches to therapy. Behavioral Neurology. 2021; 1: 28-35. (In Russ.)

6.Solovieva A.V., Chichanovskaya L.V., Bakhareva O.N., Bryanceva M.V. Study of the effectiveness of the drug Cereton in the treatment of elderly patients suffering from chronic cerebral ischemia. RMJ. 2009; 23: 1522. (In Russ.)

7.Pizova NV. The use of cereton in patients with chronic brain ischemia and moderate cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2014; 114 (12): 78‑83. https://doi.org/10.17116/jnevro201411412178-83 (In Russ.)

8.Levin O.S., Vasenina E.E., Nebozhin A.I., Nikitina A.Yu. Treatment algorithm for chronic vertebrogenic back pain: the role of chondroprotectors. The Clinician. 2023; 17(2): 55-66. https://doi.org/10.17650/1818-8338-2023-17-2-K686 (In Russ.)

9.Batysheva T.T., Nesterova O.S., Otcheskaya O.V., et al. Use of Cereton in patients with moderate cognitive impairment of vascular genesis. Difficult patient. 2009; 7 (4): 10-12. (In Russ.)

10.Gavrilova S.I., Kolykhalov I.V., Ponomareva E.V., Fedorova I.B., Selezneva N.D. Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118 (5): 45‑53. https://doi.org/10.17116/jnevro20181185145 (In Russ.)

11.Gavrilova S.I., Alesenko A.V., Kolyhalov I.V., Fedorova Ya.B., Selezneva N.D., Ponomareva E.V., Guryanova S.V., Gutner U.A., Shupik M.A. Clinical and biological effects of cereton (choline alfoscerate) in the treatment of mild cognitive decline syndrome of the amnestic type. Psychiatry. 2017; 1: 5-15. (In Russ.)

12.Shavlovskaya O.A. DMOADs and DMARDs in the treatment of patients with joint and spine diseases. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (4): 700-707. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.226 (In Russ.)

13.Gromova O.A., Torshin I.Y., Lila A.M. On the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritis. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (6): 122-130. https://doi.org/10.14412/2074-2711-2022-6-122-130 (In Russ.)

14.Lila A.M., Gromova O.A., Torshin I.Y., Nazarenko A.G., Gogolev A.Y. Molecular effects of chondroguard in osteoarthritis and herniated discs. Neurology, Neuropsychiatry, Psychosomatics. 2017; 9 (3): 88-97. https://doi.org/10.14412/2074-2711-2017-3-88-97 (In Russ.)

15.Torshin I.Yu., Lila A.M., Naumov A.V. et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388-399. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.)

16.Shavlovskaya O.A., Romanov I.D., Prokofyeva Y.S. Experience with chondroitin sulfate in the combination therapy of lower back pain. Neurology, Neuropsychiatry, Psychosomatics. 2020; 12 (3): 75-81. https://doi.org/10.14412/2074-2711-2020-3-75-81 (In Russ.)

17. Voloshin V.P., Eremin A.V., Sankaranarayanan S.A. et al. Study of the effectiveness of the drug Chondrogard (chondroitin sulfate) in patients with osteoarthritis. Difficult patient. 2015; 13 (3): 29-32. (In Russ.)

18. Honvo G., Bruyère O., Geerinck A., Veronese N., Reginster J.Y. Efficacy of Chondroitin Sulfate in Patients with Knee Osteoarthritis: A Comprehensive Meta-Analysis Exploring Inconsistencies in Randomized, Placebo-Con- trolled Trials. Adv Ther. 2019 May; 36 (5): 1085-1099. https://doi.org/10.1007/s12325-019-00921-w

19. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long- term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, dou- ble-blind, placebo-controlled trial. Arthritis Rheum. 2009 Feb; 60 (2): 524-533. https://doi.org/10.1002/art.24255

20.Sarvilina I.V., Minasov T.B., Lila A.M., et al. On the effectiveness of the parenteral form of highly purified chondroitin sulfate in the perioperative preparation for knee arthroplasty. RMJ. 2022; 7: 7-16. (In Russ.)

21.Minasov T.B., Lila A.M., Nazarenko A.G. et al. Stratification of decompensated osteoarthritis and modern options of the preoperative therapy using Chondroguard® based on pheno- and endotyping. Russian Medical Inquiry. 2023; 7 (3): 124-136. https://doi.org/10.32364/2587-6821-2023-7-3-124-136. (In Russ.)

22.Minasov T.B., Sarvilina I.V., Lila A.M., Gromova O.А., Nazarenko A.G., Zagorodniy N.V. Subchondral bone remodeling and angiogenesis in decompensated osteoarthritis: evolution of therapeutic targeting. RMJ. 2023; 8: 8–14. (In Russ.)

23. Klein R.G., Eek B.C., O’Neill C.W., Elin C., Mooney V., Derby R.R. Biochemical injection treatment for discogenic low back pain: a pilot study. Spine J. 2003 May-June; 3 (3): 220-226. https://doi.org/10.1016/s1529-9430(02)00669-1

24.Sarvilina I.V., Lila A.M., Gromova O.A. New composition of pharmaceutical nutraceutical for antigen-specific prevention and adjunctive therapy of musculoskeletal diseases. RMJ. 2023; 2: 44-50. (In Russ.)

25. Gromova О.А., Lila А.М., Torshin I.Yu., Reier I.А. Application of chondroprotective agents to inhibit osteodestructive processes in the subchondral bone in patients with osteoarthritis. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022; 15 (1): 107-118. https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.126 (In Russ.)

26.Danilov A.B., Lila A.M., Majidova Y.N. et al. New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council. Neurology, Neuropsychiatry, Psychosomatics. 2023; 15 (2): 134-146. https://doi.org/10.14412/2074-2711-2023-2-134-146 (In Russ.)

ADDITIONAL INFORMATION

Andrei P. Rachin, Dr. Sci. (Med.), Professor, President of the National Association of Experts in Comorbid Neurology, Moscow, Russia. E-mail: 7851377@gmail.com. ORCID: https://orcid.org/0000-0003-4266-0050

Author contributions. Author confirms the compliance of their authorship, according to international ICMJE criteria (authors made a significant contribution to the development of the concept, research and preparation of the article, read and approved the final version before publication Rachin A.P. – searched for suitable literature, correcting the text in accordance with the basic requirements.

Funding. The author declares no external funding for this publication.

Disclosure. The author declare no conflict of interest.

The content is available under the Creative Commons Attribution 4.0 License.

©2024. Andrei P. Rachin